Azenta Reports Q4 2026 Revenue of $167 Million and Provides FY 2027 Guidance
Azenta, Inc. (AZTA) reported fourth-quarter revenue of $167 million, representing a 2% organic growth rate. The company's Sample Management Solutions segment grew 4% organically to $94 million, driven by momentum in biorepositories and consumables. Conversely, the Multiomics segment saw a 1% organic decline to $73 million, impacted by the timing of orders and a transition away from legacy Sanger sequencing technology. Looking ahead to fiscal year 2027, Azenta issued revenue guidance between $648 million and $660 million, targeting organic growth of 3% to 5%. The company expects Adjusted EBITDA margin expansion of 200 to 250 basis points. Strategic moves include the acquisition of SynPlexity and a licensing agreement with Elegen for cell-free DNA synthesis technology, alongside an expected $11 million in annualized restructuring savings.